NTHI (NeOnc Technologies Holdings) ROCE %: 0.00% (As of Mar. 2026)


NTHI NeOnc Technologies Holdings Inc NTHI
7 GF Score
Price $4.41
! 1 Warning Sign
View Full Analysis

What is NeOnc Technologies Holdings ROCE %?

NeOnc Technologies Holdings NTHI -0.90% 7 ROCE % is 0.00% as of Mar. 2026. GuruFocus rates NTHI with a GF Score™ of 7/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. NeOnc Technologies Holdings's annualized ROCE % for the quarter that ended in Mar. 2026 was 0.00%.

NeOnc Technologies Holdings  (NAS:NTHI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

NeOnc Technologies Holdings ROCE % Related Terms

NeOnc Technologies Holdings ROCE % Historical Data

* Premium members only.

The historical data trend for NeOnc Technologies Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeOnc Technologies Holdings ROCE % Chart

NeOnc Technologies Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
0.00 0.00 0.00 0.00 0.00

NeOnc Technologies Holdings Quarterly Data
Dec21 Sep22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NTHI
7GF Score
NeOnc Technologies Holdings Inc NTHI
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeOnc Technologies Holdings ROCE % Calculation

NeOnc Technologies Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-59.642/( ( (3.417 - 8.922) + (2.824 - 20.041) )/ 2 )
=-59.642/( (-5.505+-17.217)/ 2 )
=-59.642/-11.361
=524.97 %

NeOnc Technologies Holdings's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-31.348/( ( (2.824 - 20.041) + (3.33 - 16.288) )/ 2 )
=-31.348/( ( -17.217 + -12.958 )/ 2 )
=-31.348/-15.0875
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
NeOnc Technologies Holdings (NTHI) has a ROCE % of 0.00% as of Mar. 2026.
Is NeOnc Technologies Holdings' ROCE % too high?
NeOnc Technologies Holdings' current ROCE % is 0.00%. Overall, NeOnc Technologies Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does NeOnc Technologies Holdings' ROCE % compare to GUTS and PEPG?
NeOnc Technologies Holdings' ROCE % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. NeOnc Technologies Holdings's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeOnc Technologies Holdings stock overvalued right now?
NeOnc Technologies Holdings (NTHI) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. NeOnc Technologies Holdings' overall GF Score™ is 7/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For NeOnc Technologies Holdings (NTHI), the current ROCE % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeOnc Technologies Holdings Business Description

Address 23975 Park Sorrento, Suite 205, Calabasas, CA, USA, 91302
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
7GF Score

Get the complete analysis for NTHI

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.41
Price